Literature DB >> 6611645

The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog.

S R Hamann, G D Todd, R G McAllister.   

Abstract

The relative distribution of verapamil and its demethylated metabolite, norverapamil, was studied in rats at intervals after intraperitoneal injection of the parent drug (30 mg/kg). This route of drug administration simulated oral drug dosing, and the highest concentrations of both unchanged drug and metabolite were found in the liver, with lung and kidney containing most of the remainder. The rates of disappearance of verapamil from various organs followed first-order kinetics, and the most rapid elimination occurred from brain and liver. In contrast, verapamil was given intravenously to 3 dogs by a bolus-infusion method to produce sustained steady state plasma concentrations (80, 140, 250 ng/ml) for 1, 2, and 3 h. After systemic administration, the lungs contained almost half the tissue verapamil and, 20% was found in kidney, with the liver accounting for only 17%. Norverapamil was not found in plasma or brain. These studies contrast the pattern of tissue distribution of verapamil after different routes of drug administration. The variable rates of drug elimination from specific tissues may explain the differing durations of the drug's observed effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6611645     DOI: 10.1159/000137823

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  11 in total

1.  Exercise and the pharmacokinetics of propranolol, verapamil and atenolol.

Authors:  M A van Baak; J M Mooij; P M Schiffers
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  An examination of the anticonvulsant properties of voltage-sensitive calcium channel inhibitors in amygdala kindled seizures.

Authors:  C M Mack; M E Gilbert
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Verapamil-induced changes in central conduction in patients with multiple sclerosis.

Authors:  R L Gilmore; E J Kasarskis; R G McAllister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

5.  Human liver microsomal metabolism of paclitaxel and drug interactions.

Authors:  P B Desai; J Z Duan; Y W Zhu; S Kouzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

6.  Time-course of changes in water, sodium, potassium and calcium contents of various brain regions in rats after systemic kainic acid administration.

Authors:  L Sztriha; F Joó; P Szerdahelyi
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

Review 7.  Clinical pharmacokinetics of verapamil.

Authors:  S R Hamann; R A Blouin; R G McAllister
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

8.  The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

Authors:  Jianmin Duan; Gordon Bolger; Michel Garneau; Ma'an Amad; Joëlle Batonga; Hélène Montpetit; François Otis; Martin Jutras; Nicole Lapeyre; Manon Rhéaume; George Kukolj; Peter W White; Richard C Bethell; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

9.  Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.

Authors:  S Merry; P Flanigan; E Schlick; R I Freshney; S B Kaye
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

10.  Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.

Authors:  M J Millward; B M Cantwell; N C Munro; A Robinson; P A Corris; A L Harris
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.